ENTA Stock Analysis: Enanta Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 326m USD | 12M Return: 0.8% | US29251M1062 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.05M
Qual. Beats: -1
Rev. Trend: -77.2%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs targeting virology and immunology indications. Its pipeline spans multiple programs, including EDP-514 in Phase 1b for chronic hepatitis B (HBV), zelicapavir and EDP-323 in Phase II for respiratory syncytial virus (RSV), and EDP-235 in Phase II for human coronaviruses, alongside earlier-stage candidates such as EDP-978 for chronic spontaneous urticaria and EPS-3903 for atopic dermatitis. The company also retains economics on glecaprevir, an HCV protease inhibitor developed under a long-standing collaboration with Abbott Laboratories.
As a small molecule developer, Enanta operates within a segment of biotechnology that focuses on chemically synthesized compounds rather than large-molecule biologics, which can offer advantages in manufacturing, stability, and oral administration. The companys collaboration with Abbott for HCV protease inhibitors reflects a common biotech business model in which smaller firms retain development and royalty rights while partnering with larger pharmaceutical companies for late-stage development, manufacturing, and commercialization.
- Mavyret royalties from AbbVie anchor recurring revenue
- Zelicapavir Phase II RSV data readout is key catalyst
- Pipeline expansion into HBV and immunology indications
| Net Income: -63.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 13.64 > 1.0 |
| NWC/Revenue: 229.0% < 20% (prev 274.9%; Δ -45.89% < -1%) |
| CFO/TA -0.12 > 3% & CFO -35.3m > Net Income -63.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.1m) vs 12m ago 36.43% < -2% |
| Gross Margin: 92.97% > 18% (prev 100.0%; Δ -7.03% > 0.5%) |
| Asset Turnover: 21.83% > 50% (prev 21.53%; Δ 0.30% > 0%) |
| Interest Coverage Ratio: -3.89 > 6 (EBIT TTM -50.2m / Interest Expense TTM 12.9m) |
| A: 0.50 (Total Current Assets 203.6m - Total Current Liabilities 54.2m) / Total Assets 296.9m |
| B: -1.51 (Retained Earnings -449.5m / Total Assets 296.9m) |
| C: -0.17 (EBIT TTM -50.2m / Avg Total Assets 298.9m) |
| D: 0.52 (Book Value of Equity 101.1m / Total Liabilities 195.8m) |
| Altman-Z'' = -2.22 = D |
| DSRI: 0.78 (Receivables 6.53m/8.36m, Revenue 65.3m/64.8m) |
| GMI: 1.08 (GM 100.0% / 92.97%) |
| AQI: 7.47 (AQ_t 0.09 / AQ_t-1 0.01) |
| SGI: 1.01 (Revenue 65.3m / 64.8m) |
| TATA: -0.09 (NI -63.2m - CFO -35.3m) / TA 296.9m) |
| Beneish M = 0.69 (Cap -4..+1) = D |
As of October 18, 2026, the stock is trading at USD 11.10 with a total of 215,412 shares traded. Over the past week, the price has changed by -11.20%, over one month by -11.34%, over three months by -19.21% and over the past year by +0.82%.
Current recommended Stop Loss: 10.30 (which is 7.2% or 1.3 ATR below the current price).
Enanta Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ENTA.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.8 | 96.7% |
P/E Forward = 44.0529
P/S = 4.9898
P/B = 3.4437
Revenue TTM = 65.3m USD
EBIT TTM = -50.2m USD
EBITDA TTM = -45.3m USD
Long Term Debt = 51.8m USD (estimated: total debt 55.7m - short term 3.91m)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 55.7m USD (from shortLongTermDebtTotal, last quarter) (leases 55.7m already included)
Net Debt = -101.1m USD (calculated: Debt 55.7m - CCE 156.7m)
Enterprise Value = 224.6m USD (325.6m + Debt 55.7m - CCE 156.7m)
Interest Coverage Ratio = -3.89 (Ebit TTM -50.2m / Interest Expense TTM 12.9m)
EV/FCF = -5.03x (Enterprise Value 224.6m / FCF TTM -44.7m)
FCF Yield = -19.89% (FCF TTM -44.7m / Enterprise Value 224.6m)
FCF Margin = -68.45% (FCF TTM -44.7m / Revenue TTM 65.3m)
Net Margin = -96.89% (Net Income TTM -63.2m / Revenue TTM 65.3m)
Gross Margin = 92.97% ((Revenue TTM 65.3m - Cost of Revenue TTM 4.59m) / Revenue TTM)
Gross Margin QoQ = 91.58% (prev 92.95%)
Tobins Q-Ratio = 0.76 (Enterprise Value 224.6m / Total Assets 296.9m)
Interest Expense / Debt = 23.21% (Interest Expense 12.9m / Debt 55.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -39.7m (EBIT -50.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.54 (Total Current Assets 203.6m / Total Current Liabilities 57.5m)
Debt / Equity = 0.55 (Debt 55.7m / totalStockholderEquity, last quarter 101.1m)
Debt / EBITDA = 2.23 (negative EBITDA) (Net Debt -101.1m / EBITDA -45.3m)
Debt / FCF = 2.26 (negative FCF - burning cash) (Net Debt -101.1m / FCF TTM -44.7m)
Total Stockholder Equity = 102.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.15% (Net Income -63.2m / Total Assets 296.9m)
RoE = -61.84% (Net Income TTM -63.2m / Total Stockholder Equity 102.2m)
RoCE = -32.61% (EBIT -50.2m / Capital Employed (Equity 102.2m + L.T.Debt 51.8m))
RoIC = -16.30% (negative operating profit) (NOPAT -39.7m / Invested Capital 243.3m)
WACC = 11.55% (E(325.6m)/V(381.3m) * Re(10.39%) + D(55.7m)/V(381.3m) * Rd(23.21%) * (1-Tc(0.21)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.15 | Cagr: 15.18%
[DCF] Fair Price = unknown (Cash Flow -44.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.10 | # QB: -1
Revenue Correlation: -77.16 | Revenue CAGR: -5.34% | SUE: -1.12 | # QB: -1
EPS current Quarter (2026-12-31): EPS=-0.41 | Chg30d=-10.96% | Revisions=-25% | Analysts=2
EPS current Year (2026-09-30): EPS=-2.29 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=+40.3% | GrowthRev=-2.0%
EPS next Year (2027-09-30): EPS=-2.37 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=-3.6% | GrowthRev=-0.4%
[Analyst] Revisions Ratio: -62% (up=0, down=5)